Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Catherine R Marinac, PhD
Dana-Farber Cancer Institute
Study Director - Omar Nadeem, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber at Brighton
Brighton, Massachusetts, United States
- Dana-Farber at Merrimack Valley
Methuen, Massachusetts, United States
- Dana-Farber at Milford
Milford, Massachusetts, United States
- Df/ Bwcc in Clinical Affiliation With South Shore Hospital
Weymouth, Massachusetts, United States
- Dana-Farber at Nhoh
Londonderry, New Hampshire, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Apr 2021
- Primary completion
- 29 Jan 2025
- Completion
- 31 Jul 2027
- Last update posted
- 9 Feb 2026
- Registered enrollment
- 60
- Registry id
- NCT04850846
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.